|
|
|
|
| LEADER |
04922nam a22004213i 4500 |
| 001 |
EBC6122108 |
| 003 |
MiAaPQ |
| 005 |
20231204023214.0 |
| 006 |
m o d | |
| 007 |
cr cnu|||||||| |
| 008 |
231204s2020 xx o ||||0 eng d |
| 020 |
|
|
|a 9783030359188
|q (electronic bk.)
|
| 020 |
|
|
|z 9783030359171
|
| 035 |
|
|
|a (MiAaPQ)EBC6122108
|
| 035 |
|
|
|a (Au-PeEL)EBL6122108
|
| 035 |
|
|
|a (OCoLC)1143625864
|
| 040 |
|
|
|a MiAaPQ
|b eng
|e rda
|e pn
|c MiAaPQ
|d MiAaPQ
|
| 050 |
|
4 |
|a RS400-431
|
| 100 |
1 |
|
|a Schweizer, Lars.
|
| 245 |
1 |
0 |
|a Advances in Pharma Business Management and Research :
|b Volume 1.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing AG,
|c 2020.
|
| 264 |
|
4 |
|c ©2020.
|
| 300 |
|
|
|a 1 online resource (93 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Intro -- Preface -- Contents -- About the Editors -- Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry -- Relevance of Instruments for Measurements of Quality of Life in the AMNOG Context: An Analysis of the Endpoint Health-Related ... -- 1 Relevance of Instruments for Measurements of Quality of Life in the AMNOG Context -- 1.1 An Analysis of the Endpoint Health-Related Quality of Life from Different Perspectives -- 2 Methods -- 3 Results and Conclusions -- 4 Outlook -- References -- Quality Management System for RandD Project and Portfolio Management in Pharmaceutical Company -- 1 Introduction -- 2 Theoretical Background -- 2.1 Theories -- 2.2 Pharmaceutical Project Management Quality System Model -- 2.3 Hypotheses -- 3 Empirical Analysis -- 3.1 Methodology -- 3.1.1 Characterization of PPMQS Enabling and Result Systems -- 3.2 Testing of Hypotheses -- 4 Empirical Findings -- 4.1 Characterization of Enabling and Result Systems -- 4.2 Testing of Hypotheses -- 5 Discussion -- References -- Brexit and Its Impact on Pharmaceutical Law: Implications for Global Pharma Companies -- 1 Brexit Scenarios -- 2 Impact on the Drug Regulatory Framework -- 3 Recommended Actions for Companies -- 4 Conclusions and Outlook -- References -- Implementation of Measurable and Sustainable Actions to Improve Employeeś Engagement and Business Performance: Global Medical... -- 1 Background -- 2 Statement of Expectations -- 2.1 With Onboarding the Bond of Employees to the Company will be Increased -- 2.2 Regular Feedback Meetings with Superiors will Engage Employees -- 2.3 Personal Development Plans will Lead to Better Performance -- 3 Managerial Implications -- 3.1 Implications on Fresenius Kabi -- 4 Direction for Future Research -- 5 Conclusion -- References.
|
| 505 |
8 |
|
|a Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership -- 1 The Importance of Leadership for Corporate Success -- 2 The Concept of Leadership -- 3 Constructs and Generation of Hypotheses -- 4 Empirical Assessment of the Models -- 5 Summary, Implications and Outlook -- References -- Alliance Management at Merck: Establishing an Operational 100-Day Plan for Alliance Launches and Management -- 1 Introduction -- 2 The Importance of Alliances for the Pharmaceutical Industry -- 2.1 The Problem ``Productivity Paradox ́́-- 2.2 Cooperation as a Potential Solution -- 3 The Nature of Alliances -- 3.1 Definitions and Types of Alliances -- 3.2 The Lifecycle of Alliances -- 3.3 The Role of the Alliance Management -- 4 Merck KGaA and Its Alliances -- 4.1 History of Merck KGaA -- 4.2 Significant Biopharma Alliances of Merck -- 4.3 Alliance Management at Merck -- 5 The Operational 100-Day Plan -- 6 The Online Survey on the 100-Day Plan -- 6.1 General Statistics -- 6.2 Alliance Launch Phase -- 6.3 Governance of Alliances -- 6.4 Evaluation of Alliances -- 6.5 Feedback on the 100-Day Plan -- 7 Conclusion and Outlook -- Appendix 1: Operational 100-Day Plan for Alliance Launch -- References -- Correction to: Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry -- Correction to: Chapter 1 in: L. Schweizer et al. (eds.), Advances in Pharma Business Management and Research, https://doi.org/.
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Dingermann, Theodor.
|
| 700 |
1 |
|
|a Russe, Otto Quintus.
|
| 700 |
1 |
|
|a Jansen, Christian.
|
| 776 |
0 |
8 |
|i Print version:
|a Schweizer, Lars
|t Advances in Pharma Business Management and Research
|d Cham : Springer International Publishing AG,c2020
|z 9783030359171
|
| 797 |
2 |
|
|a ProQuest (Firm)
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/matrademy/detail.action?docID=6122108
|z Click to View
|
